Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Certepetide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lisata Pharma Terminates Certepetide License Agreement With Qilu
    Lisata Pharma Terminates Certepetide License Agreement With Qilu

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226416/18623/en/Lisata-Therapeutics-Announces-Mutual-Termination-of-License-Agreement-with-Qilu-Pharmaceutical-for-Certepetide.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    Cancer Imaging Company Buys Lisata For Ph. 2-Stage Tumor Drug
    Cancer Imaging Company Buys Lisata For Ph. 2-Stage Tumor Drug

    21 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cancer-imaging-company-buys-lisata-phase-2-stage-solid-tumor-drug

    FIERCE BIOTECH
    21 Jan 2026
    Share Share
    Lisata Therapeutics Showcases Certepetide Preclinical Data
    Lisata Therapeutics Showcases Certepetide Preclinical Data

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180798/18623/en/Lisata-Therapeutics-Highlights-Positive-Preclinical-Data-of-Certepetide-as-Part-of-Antibody-Drug-Conjugate-Combinations-as-Reported-by-Licensing-Partner-Catalent.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Lisata & Catalent Announce Global ADC License Agreement
    Lisata & Catalent Announce Global ADC License Agreement

    08 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/08/3163348/18623/en/Lisata-Therapeutics-and-Catalent-Announce-Global-Antibody-Drug-Conjugate-ADC-License-Agreement.html

    GLOBENEWSWIRE
    08 Oct 2025
    Share Share
    Lisata Therapeutics Gains New Patent for Certepetide Composition
    Lisata Therapeutics Gains New Patent for Certepetide Composition

    15 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/15/3115507/18623/en/Lisata-Therapeutics-Expands-Intellectual-Property-Portfolio-with-New-Composition-of-Matter-Patent-for-Certepetide.html

    GLOBENEWSWIRE
    15 Jul 2025
    Share Share
    Lisata Therapeutics Announces Research License with Catalent
    Lisata Therapeutics Announces Research License with Catalent

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061666/18623/en/Lisata-Therapeutics-Announces-Research-License-with-Catalent.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.